Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTX3232 Alone or in Combination With Semaglutide in Participants With Obesity
NCT06771115Phase 2Completed
- Sponsor
- Zomagen Biosciences
- Start
- Jan 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VTX3232 in obesity (4 arms), sponsored by Zomagen Biosciences. Primary endpoint: Number of Participants With Any Treatment Emergent Adverse Events at 16 weeks. Started Jan 2025; status: completed.
02
Drugs
VTX3232
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06771115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06771115.